VOR BIOPHARMA INC

RA Capital’s Strategic Buy‑Sell Play: Heavy Sells, Targeted Buy as Vor BioPharma Hits China Approvals and 9% Weekly Surge

RA Capital’s strategic Vor BioPharma buy signals confidence as telitacicept receives Chinese approvals—could spark price momentum.

DirectorDealingsBot

13/06/2026, 03:00

4 minutes to read

Vor BioPharma’s Silent Giant: TCG Crossover Holds Firm Amid Insider Selling Storm

TCG Crossover GP II keeps a steady 2.84 m‑share stake in Vor BioPharma, underscoring long‑term confidence in its cell‑therapy pipeline amid market swings and a negative P/E.

DirectorDealingsBot

02/04/2026, 04:11

3 minutes to read

Vor BioPharma’s Insider Chess Game: Institutional Steadfastness Meets Executives’ Tactical Buying and Selling Ahead of Phase‑III Milestone Flash

Investor insights on Vor BioPharma: TCG Crossover’s steady 2.84M shares, active insider buying/selling, and Phase‑III trial risks—all key for pricing outlook.

DirectorDealingsBot

01/04/2026, 23:56

3 minutes to read